These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11555106)

  • 1. Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
    Tsutsumi M; Ueshima Y; Takase S
    J Gastroenterol Hepatol; 2001 Aug; 16(8):910-5. PubMed ID: 11555106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
    Murdoch D; McTavish D
    Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers.
    Nakamura H; Kawashima H; Azuma R; Sato I; Nagao K; Miyazawa K
    Drug Metab Pharmacokinet; 2012; 27(4):422-9. PubMed ID: 22293541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
    Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
    Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect].
    Chen WW; Kolsky H; Lewin MJ; Bonfils S
    Gastroenterol Clin Biol; 1990; 14(4):342-6. PubMed ID: 1972124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
    Merki HS; Bender W; Labs R
    J Clin Gastroenterol; 1989; 11 Suppl 1():S20-3; discussion S24. PubMed ID: 2572621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
    Lameire N; Rosenkranz B; Brockmeier D
    Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of roxatidine in healthy volunteers.
    Collins JD; Pidgen AW
    Drugs; 1988; 35 Suppl 3():41-7. PubMed ID: 2905248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.
    Gladziwa U; Wagner S; Sieberth HG; Klotz U
    Br J Clin Pharmacol; 1995 Feb; 39(2):161-7. PubMed ID: 7742154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
    Collins JD
    Scand J Gastroenterol Suppl; 1988; 146():89-99. PubMed ID: 2906472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.
    Tanaka E; Nakamura K
    Br J Clin Pharmacol; 1989 Aug; 28(2):171-4. PubMed ID: 2570603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of the histamine H2 receptor antagonist roxatidine acetate on stomach and liver alcohol dehydrogenase and serum alcohol level].
    Beil W; Sewing KF
    Z Gastroenterol; 1993 Nov; 31(11):643-5. PubMed ID: 7904786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.
    Inoue M
    Drugs; 1988; 35 Suppl 3():114-9. PubMed ID: 2905239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of roxatidine into the cerebrospinal fluid.
    Tryba M; Kurz-Muller K
    Scand J Gastroenterol Suppl; 1988; 146():153-8. PubMed ID: 2906459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic characteristics of roxatidine.
    Bender W; Brockmeier D
    J Clin Gastroenterol; 1989; 11 Suppl 1():S6-19. PubMed ID: 2572622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Roxatidine in the treatment of gastroduodenal mucosal lesions in hepatic cirrhosis].
    Sardini C; Ventura P; Abbati GL; Rigo G; Cioni G; Cristani A; Tincani E; Ventura E
    Recenti Prog Med; 1994 Nov; 85(11):517-20. PubMed ID: 7855384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. The European Cooperative Roxatidine Study Group.
    Clin Ther; 1991; 13(1):47-57. PubMed ID: 1674231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
    Hemery P; Congard P; Galmiche JP; Bonfils S
    Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effective prevention of indomethacin-induced gastroduodenal mucosal lesions with roxatidine acetate].
    Dammann HG; Wolf N; Burkhardt F
    Arzneimittelforschung; 1995 Aug; 45(8):880-2. PubMed ID: 7575752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.